Background: Recent data indicate the elevated serum high-sensitivity C-reactive protein (hs-CRP) level predicts the risk of recurrent coronary events. And statin therapy has been shown to decrease the risk of coronary events. This study assessed the relation between pre-procedural hs-CRP and in-stent neointimal hyperplasia (NIH) after stenting and examined the effects of statins on the relationship between the restenosis development after stenting and the serum hs-CRP levels of patients with coronary artery disease. Methods: This study included 100 patients who underwent stent implantation for angiographically significant stenosis. Patients were divided into a normal CRP group (< 0.5mg/dL) and elevated CRP group (��� 0.5mg/dL) on the basis of serum CRP levels. Results: All patients underwent angiographic and intravascular ultrasound follow-up at six months. The baseline CRP level was 0.29짹0.08 mg/dL in the normal CRP group and 2.90짹2.31 mg/dL in the elevated CRP group. The NIH cross sectional area (CSA) in the minimal lumen CSA at follow-up was significantly larger in the elevated CRP group (1.9짹1.3mm2 vs. 3.0짹1.5mm2, p=0.001). A significant positive correlation was found between pre-interventional CRP levels and NIH area (r=0.52, p<0.001). In patients with normal CRP, association between the use of statin and the restenosis development was not observed. However, when the analysis was confined to patients with elevated CRP, statin therapy significantly reduced the restenosis rate (24% vs. 36%, p=0.031). Conclusions: Measuring pre-interventional hs-CRP levels may be helpful to predict restenosis after stenting and statin therapy significantly reduced restenosis rate in patients with elevated hs-CRP.